Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/19/2017 10:26:16 AM - Followers: 76 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#3093   Most people do, as do I. 6 month-report Gene_Simmons 10/19/17 10:26:16 AM
#3092   Why do you predict them to be released suerte88 10/19/17 09:23:17 AM
#3091   Huge news next week if we are lucky. Gene_Simmons 10/19/17 08:32:06 AM
#3090 suerte88 10/12/17 04:36:03 AM
#3089   Technical question, would this process be particularly effective Jack 7794 10/11/17 09:31:41 PM
#3088   Thanks Flenderson. I hope you are well. I CUIN2 10/11/17 02:58:51 PM
#3087   CUIN, sorry for the delayed response. I don't Flenderson 10/11/17 02:47:32 PM
#3086   Calm before the strorm. We will go 3 123414 10/09/17 10:06:36 AM
#3085   i don't know of any. however we may heavymetal 10/06/17 07:57:10 PM
#3084   Would there be any other Biotech boards that -3 09/29/17 07:39:35 AM
#3083   Yep 3 patients about to get their sign MIKE22CA 09/27/17 12:49:05 PM
#3082   LIKE abun 09/27/17 10:22:56 AM
#3081   my advice. heavymetal 09/26/17 06:58:09 PM
#3080   Look at the trajectory from late August 2015 123414 09/26/17 06:50:50 AM
#3079   “TLD-1433 continues to advance preclinically and clinically" 123414 09/25/17 02:01:26 PM
#3078   "the strong safety profile observed in TLD-1433 treated 123414 09/25/17 01:53:26 PM
#3077   Simply amazing technology! These guys impress me every Anesthesia 2007 09/25/17 08:02:26 AM
#3076   Thanks. You too. CUIN2 09/25/17 07:30:03 AM
#3075   Theralase Lead Anti-Cancer Drug Effective in the Destruction suerte88 09/25/17 07:29:07 AM
#3074   Ok CUIN2 that's cool, it's just the PR 123414 09/25/17 04:03:13 AM
#3073   It does in the context/combination of the words CUIN2 09/24/17 10:16:16 PM
#3072   Hi CUIN2 My only contention with your post 123414 09/24/17 11:44:28 AM
#3071   6 month follow-up. First three results in CUIN2 09/24/17 10:42:43 AM
#3070   CUIN2 wrote: the below PR (which he and 123414 09/24/17 09:41:34 AM
#3069   my opinion: heavymetal 09/22/17 12:09:02 PM
#3068   He shouldn't be surprised. When he was CUIN2 09/21/17 07:45:00 PM
#3067   If it's true that PMH holds the 'privacy' MIKE22CA 09/21/17 12:24:20 PM
#3066   I talked to Roger last Wednesday about the Anesthesia 2007 09/21/17 09:29:50 AM
#3065   The website still says Theralase is still enrolling CUIN2 09/20/17 09:43:06 PM
#3064   I love Theralase's story, Roger and the team. CUIN2 09/19/17 07:31:09 PM
#3063   Will buy back my shares around january next suerte88 09/19/17 12:37:55 PM
#3062   That's Theralase's reports i.e. podcast ... they are MIKE22CA 09/19/17 12:23:53 PM
#3061   It wont happen. They mentioned some uplisting possibility suerte88 09/19/17 12:10:21 PM
#3060   Expanding pipeline fast as possible MIKE22CA 09/19/17 09:44:04 AM
#3059   Theralase Lead Anti-Cancer Drug Effective in the Destruction suerte88 09/19/17 07:32:16 AM
#3058   Short volume dropping substantially. 123414 09/18/17 12:29:13 PM
#3057   Theralase Demonstrates 24 Month Stability of Lead Anti-Cancer CUIN2 09/18/17 07:18:20 AM
#3056 heavymetal 09/18/17 05:43:25 AM
#3055   The reason they will do a 6 month 123414 09/17/17 11:46:27 PM
#3054   It will be substantially increased in value because 123414 09/16/17 07:55:26 AM
#3053   Really pumped. Think this will be the real abun 09/15/17 01:40:36 PM
#3052   TLTFF The real deal here, just read up. 123414 09/15/17 12:17:30 PM
#3051   Great presentation. What is even better is SurgGuy 09/14/17 08:24:53 AM
#3050   New 3rd Q Powerpoint Presentation itsallgood11 09/14/17 07:27:34 AM
#3049   Exciting stuff! It's really exciting that they're getting Anesthesia 2007 09/12/17 10:28:36 AM
#3048   And the portfolio grows. SG SurgGuy 09/12/17 09:51:11 AM
#3047   Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug Toronto, Anesthesia 2007 09/12/17 07:04:48 AM
#3046   I wonder what dr. Frost is up to? Gene_Simmons 09/10/17 02:38:16 PM
#3045   As I surmised many months ago, results from CUIN2 09/08/17 08:51:35 PM
#3044 itsallgood11 09/08/17 04:31:19 PM